Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adam Arceneaux

Internal Medicine Houma, LA Medical Doctor

NPI 1538571252 CMS profile 3127237

8120 Main St Ste 403, Houma, LA 70360

Open in the dashboard

General payments

$5,662

222 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam Arceneaux of Houma, LA is reported in the CMS Open Payments database as having received $5,662 across 222 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $448 16
2024 General $685 11
2023 General $487 9
2022 General $1,092 16
2021 General $674 24
2020 General $776 50
2019 General $1,499 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Arceneaux
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Adam Arceneaux were reported at $448. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Adam Arceneaux Internal Medicine median Middle half National median
2019 $1,499 $159 $48–$570 $163
2020 $776 $119 $33–$402 $114
2021 $674 $135 $37–$521 $132
2022 $1,092 $141 $42–$496 $149
2023 $487 $149 $45–$519 $160
2024 $685 $154 $47–$537 $164
2025 $448 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $776 16 payments
  2. Novo Nordisk Inc $546 23 payments
  3. Lilly USA, LLC $504 25 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $350 19 payments
  5. Allergan Inc. $255 17 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $244 14 payments
  7. AbbVie, Inc. $231 12 payments
  8. Smith+Nephew, Inc. $228 3 payments
  9. Esperion Therapeutics, Inc. $219 2 payments
  10. GlaxoSmithKline, LLC. $212 13 payments
  11. Other $2,095 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,568 221 payments
  2. Education $94 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $330 16 payments
  2. FARXIGA $305 5 payments
  3. BREZTRI $290 3 payments
  4. MOUNJARO $247 5 payments
  5. JARDIANCE Diabetes $242 11 payments
  6. TRULICITY $232 18 payments
  7. NEXLETOL $219 2 payments
  8. NEXLIZET $219 2 payments
  9. RYBELSUS $178 6 payments
  10. JARDIANCE Diabetes $171 14 payments
  11. Other $5,060 223 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 154 drugs

Part D claims

9,318

Median for Internal Medicine: 777

Drug cost

$1,352,640

Median for Internal Medicine: $73,373

Branded share of claims

26.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 165 $266,990
Farxiga Dapagliflozin Propanediol Brand 129 $121,267
Jardiance Empagliflozin Brand 79 $111,124
Ozempic Semaglutide Brand 83 $101,271
Vraylar Cariprazine Hcl Brand 61 $88,562
Synjardy Xr Empagliflozin/Metformin Hcl Brand 77 $80,556
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 92 $64,206
Eliquis Apixaban Brand 59 $60,851
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 29 $43,208
Rybelsus Semaglutide Brand 21 $35,957

The 10 drugs with the highest cost, of 154 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$75,737

Of which drugs: $4,132

Medicare patients

195

Average age 73

Services billed

1,445

103 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 41%
Diabetes 35%
Chronic kidney disease 24%
Heart failure 22%
Depression 22%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 16 16 $1,309

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $158
$158 129 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $84
$84 — —
VRAYLAR
  • AbbVie, Inc. $40
$40 61 —
RYBELSUS
  • Novo Nordisk Inc $18
$18 21 —
Ozempic
  • Novo Nordisk Inc $18
$18 83 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

222 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record